Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 1405-1410, May 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dow, L. W.
Right arrow Articles by Fridland, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dow, L. W.
Right arrow Articles by Fridland, A.

Differences in Metabolism and Cytotoxicity between 9-ß-D-Arabinofuranosyladenine and 9-ß-D-Arabinofuranosyl-2-fluoroadenine in Human Leukemic Lymphoblasts1

Lois W. Dow, Douglas E. Bell, Lawrence Poulakos and Arnold Fridland2

Divisions of Biochemical and Clinical Pharmacology [A. F., D. E. B.] and Hematology-Oncology [L. W. D., L. P.], St. Jude Children's Research Hospital, Memphis, Tennessee 38101

We compared the effects of 9-ß-D-arabinofuranosyladenine (ara-A) and its 2-fluoro derivative (F-ara-A) on DNA synthesis and viability in human leukemic lymphoblasts (CCRF-CEM). The relative DNA content and cloning capacity of the cells were determined by flow cytometry and growth in methylcellulose, respectively. Incubation with either 1 µM ara-A in the presence of 2'-deoxycoformycin, a potent inhibitor of adenosine deaminase, or 2.5 µM F-ara-A alone for 18 hr stopped the progression of cells through S phase. At higher concentrations, from 2.5 to 20 µM, both arabinonucleosides preferentially produced toxic effects in cells arrested in S phase. The DNA-inhibitory effects and cytotoxicity of F-ara-A, but not ara-A, were prevented by adding deoxycytidine to the growth medium. A CCRF-CEM variant that was unable to phosphorylate deoxycytidine proved to be highly resistant to the inhibitory effects of F-ara-A but was normally sensitive to ara-A. These results indicate that the cytotoxicity of ara-A in both sensitive and resistant cells and of F-ara-A in sensitive cells is probably mediated by the intracellular formation of nucleotides and inhibition of DNA synthesis. By contrast, the reduction in the cloning efficiency of 1-ß-D-arabinofuranosylcytosine-resistant cells at high concentrations of F-ara-A may be due to some direct effect of the nucleoside. Finally, the different susceptibility of the mutant CCRF-CEM cells to the toxic effects of ara-A and F-ara-A suggests that alternative pathways phosphorylate these arabinonucleosides, one being associated with deoxycytidine kinase and the other with either deoxyadenosine kinase or, less likely, adenosine kinase.

1 Supported by Research Project Grant CH-52A from the American Cancer Society, Research Project Grant CA-18446, Leukemia Program Project Grant CA-20180, Cancer Center Support (CORE) Grant CA-21764 from the National Cancer Institute, and American Lebanese Syrian Associated Charities (ALSAC).

2 To whom requests for reprints should be addressed, at St. Jude Children's Research Hospital, 332 N. Lauderdale, P. O. Box 318, Memphis, Tenn. 38101.

Received 8/31/79. Accepted 1/29/80.




This article has been cited by other articles:


Home page
Cancer Res.Home page
H. Gourdeau, M. L. Clarke, F. Ouellet, D. Mowles, M. Selner, A. Richard, N. Lee, J. R. Mackey, J. D. Young, J. Jolivet, et al.
Mechanisms of Uptake and Resistance to Troxacitabine, a Novel Deoxycytidine Nucleoside Analogue, in Human Leukemic and Solid Tumor Cell Lines
Cancer Res., October 1, 2001; 61(19): 7217 - 7224.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.